Clinical trials
Melanoma clinical trials
A serious form of skin cancer that develops in pigment-producing cells. We’re tracking 465 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06365619RecruitingPhase 2
Immunotherapy before surgery for recurrent melanoma
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
Salt Lake City, UtahAges 18 years+ - NCT07680699Recruiting
Early immunotherapy for high-risk stage II melanoma
This trial tests early anti-PD-1 therapy for people with stage IIB or IIC melanoma, or stage III (N1c). It aims to see if starting treatment sooner helps prevent the cancer from coming back.
São Paulo, São PauloAges 18 years+ - NCT07276386RecruitingPhase 2
Combination therapy for metastatic uveal melanoma
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Tampa, FloridaAges 18 years+ - NCT07302607Recruiting
Melanoma immunotherapy study at Strasbourg Hospital
This study looks back at medical records to find out what factors helped people with advanced melanoma respond completely to immunotherapy. It includes patients treated at a specific hospital in France between 2013 and 2021.
StrasbourgAges 18 years+ - NCT07501117RecruitingPhase 1
Immunotherapy before eye removal for high-risk eye melanoma
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
Herlev, HerlevAges 18–80 - NCT07349303RecruitingPhase 2
Pembrolizumab Before Surgery for Stage IIb/c Melanoma
This trial tests whether giving pembrolizumab (Keytruda) before surgery helps people with a certain type of advanced melanoma (stage IIb/c). The goal is to see if this treatment can improve outcomes before the tumor is removed.
GothenburgAges 18 years+ - NCT07354152Recruiting
Flap vs skin graft for melanoma wound closure
This study compares two ways of closing a large wound after melanoma removal: using a skin flap (where nearby tissue is moved to cover the defect) versus a skin graft (taking a thin layer of skin from another area). It aims to see which method works better for healing.
Nantes, NantesAges 18 years+ - NCT07364474Recruiting
Immune response to liver perfusion therapy for eye melanoma
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
Boston, MassachusettsAges 18 years+ - NCT07379138Recruiting
Talk therapy for distress in advanced melanoma
This study is testing whether a type of talk therapy (cognitive behavioral therapy) can help improve quality of life, including mental health, for people recently diagnosed with advanced melanoma. It is designed to understand and reduce cancer-related distress.
Rochester, MinnesotaAges 18 years+ - NCT00040352Recruiting
Understanding melanoma risk in families and individuals
This research study helps doctors understand why some people and families develop melanoma (a serious skin cancer), especially in unusual circumstances. Researchers will collect medical histories, examine skin, and may do genetic testing to identify risk factors that could help with earlier detection and prevention.
Bethesda, MarylandAges 4 weeks–99 years - NCT01438658Recruiting
Test blood markers to help diagnose metastatic uveal melanoma
This study checks whether blood “biomarkers” (measurable signs in serum) can help diagnose metastatic uveal melanoma. If you have uveal melanoma, the study may look at how useful these blood tests are for spotting spread to other parts of the body.
JerusalemAges Any age - NCT01638676RecruitingPhase 1/Phase 2
Testing vemurafenib plus metformin for BRAF-mutated melanoma
This study tests whether adding metformin to vemurafenib can shrink advanced melanoma in people with a specific gene change (BRAF V600E). It’s an early-phase trial, so the main goal is to see if the combination is safe and whether it may work better than expected.
Louisville, KentuckyAges 18 years+ - NCT01776905Recruiting
Real-time detection of melanoma cells during a test
This trial tests a way to detect circulating melanoma cells (melanoma cells moving in the blood) in real time. If you have melanoma, you may be asked to take part in a session where the team measures your blood during the procedure.
Little Rock, ArkansasAges 18–80 - NCT02821013RecruitingPhase 3
Testing how long to take PD-1 therapy for melanoma
This trial studies whether people with metastatic melanoma should take PD-1 immunotherapy continuously or only for a limited time. It aims to find a schedule that keeps the cancer under control while possibly reducing treatment burden.
Victoria, MilduraAges 18 years+ - NCT02828202Recruiting
Melanoma patient follow-up study for multiple tumor stages
This study follows adults with certain melanoma stages to better understand the disease over time. You may be asked to share tissue samples (if available) so researchers can study tumor biology and track outcomes.
AmiensAges 18 years+ - NCT02870244RecruitingPhase 1
Engineered T-cell therapy for advanced melanoma patients
This Phase 1 study tests a lab-made immune cell treatment for advanced melanoma. It aims to see if engineered T-cells can recognize the patient’s tumor and help control the cancer, especially in specific melanoma tissue markers.
Maywood, IllinoisAges 18–89 - NCT06246149RecruitingPhase 3
Tebentafusp after treatment for high-risk eye melanoma
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Lake Success, New YorkAges 18 years+ - NCT01205815Recruiting
Use and storage of leftover melanoma tissue for future testing
This study collects and stores leftover melanoma tissue (and sometimes blood) for future research and testing. If the trial uses your stored samples to help match treatments, it could support better care planning over time.
Nashville, TennesseeAges 18 years+ - NCT07404605Recruiting
Electrochemotherapy for skin melanoma study
This study tests if electrochemotherapy can change the environment around melanoma tumors. It may help patients with melanoma that has spread to the skin or just under the skin.
LjubljanaAges 18 years+ - NCT07405086RecruitingPhase 4
Morning vs. afternoon immunotherapy for advanced solid tumors
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Portland, OregonAges 18 years+ - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT07422779Recruiting
Immunotherapy for advanced melanoma study
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
LjubljanaAges 18 years+ - NCT07448831RecruitingPhase 2
Pembrolizumab before surgery for high-risk melanoma
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can help people with high-risk melanoma. It is for patients whose melanoma has not spread and who have not had prior treatment for melanoma.
Jette, Brussels CapitalAges 18 years+ - NCT07449754RecruitingPhase 2
Belvarafenib with cobimetinib for NRAS-mutant melanoma
This trial tests a combination of two drugs (belvarafenib and cobimetinib) for people with advanced melanoma that has a specific gene change called NRAS. It is for those who have tried other treatments or cannot take them.
Seongnam-si, Gyeonggi-doAges 19 years+
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for melanoma?
- Yes. Clin2 currently lists 465 recruiting melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.